Overview of the impact of CD8 levels on HCT outcomes in children and adults
| Reference . | Platform . | Adult/pediatric . | Outcome . | No. of patients . | Type of study . |
|---|---|---|---|---|---|
| Yakoub-Agha et al46 | Unmanipulated BMT and PBSC | Adult, pediatric | CD28neg CD8+ T cells < 179 cells per μL at day 60 associated with higher cumulative incidence of relapse | 80, single center | Prospective |
| Tian et al47 | Unmanipulated haplo | Adult, pediatric | ≥375 cells per μL at day 90 reduced infections, improved NRM, LFS, and OS | 214, single center | Prospective |
| Ranti et al48 | BMT, PBSC | Adult | >50 CD8+ T cells per μL reduces relapse incidence. No effect on OS, DFS. | 120, single center | Retrospective |
| Bondanza et al49 | Haplo (unmanipulated, CD34+, TCD) | Adult, pediatric | <20 CD8+ T cells per μL reduces OS and increases NRM | 144, multicenter | Retrospective |
| Troullioud Lucas et al21 | All | Pediatric, young adult | No association found between CD8+ T-cell IR and outcomes | 503, multicenter | Retrospective |
| Huang et al13 | All | Adult, young adult | In pts with early CD4+ T-cell recovery (>50/μL by day 100), higher CD8+ is associated with reduced EBV reactivation | 122, single center | Retrospective |
| Belinovski et al44 | All | Pediatric | On 180 day CI of CMV infection higher for patients CD3+CD8+ of ≥200/μL on day +100. | 111, single center | Retrospective |
| Soares et al14 | MUD | Adult | Early increase in CD8+ T-cell subsets in patients who later develop cGVHD | 40, single center | Prospective |
| Ando et al12 | All | Adult | Higher CD8+ T cells on day +100 reduces NRM;higher activated CD8+ T cells on day +100 increases cGVHD | 358, single center | Retrospective |
| Reference . | Platform . | Adult/pediatric . | Outcome . | No. of patients . | Type of study . |
|---|---|---|---|---|---|
| Yakoub-Agha et al46 | Unmanipulated BMT and PBSC | Adult, pediatric | CD28neg CD8+ T cells < 179 cells per μL at day 60 associated with higher cumulative incidence of relapse | 80, single center | Prospective |
| Tian et al47 | Unmanipulated haplo | Adult, pediatric | ≥375 cells per μL at day 90 reduced infections, improved NRM, LFS, and OS | 214, single center | Prospective |
| Ranti et al48 | BMT, PBSC | Adult | >50 CD8+ T cells per μL reduces relapse incidence. No effect on OS, DFS. | 120, single center | Retrospective |
| Bondanza et al49 | Haplo (unmanipulated, CD34+, TCD) | Adult, pediatric | <20 CD8+ T cells per μL reduces OS and increases NRM | 144, multicenter | Retrospective |
| Troullioud Lucas et al21 | All | Pediatric, young adult | No association found between CD8+ T-cell IR and outcomes | 503, multicenter | Retrospective |
| Huang et al13 | All | Adult, young adult | In pts with early CD4+ T-cell recovery (>50/μL by day 100), higher CD8+ is associated with reduced EBV reactivation | 122, single center | Retrospective |
| Belinovski et al44 | All | Pediatric | On 180 day CI of CMV infection higher for patients CD3+CD8+ of ≥200/μL on day +100. | 111, single center | Retrospective |
| Soares et al14 | MUD | Adult | Early increase in CD8+ T-cell subsets in patients who later develop cGVHD | 40, single center | Prospective |
| Ando et al12 | All | Adult | Higher CD8+ T cells on day +100 reduces NRM;higher activated CD8+ T cells on day +100 increases cGVHD | 358, single center | Retrospective |
BMT, BM transplantation; CI, cumulative incidence; CMV, cytomegalovirus; DFS, disease-free survival; EBV, Epstein-Barr virus; haplo, haploidentical transplant; LFS, leukemia-free survival; MUD, matched unrelated donor; PBSC, peripheral blood mononuclear cell; pts, patients.